Increased production of CXCL16 in experimental and clinical heart failure: A possible role in extracellular matrix remodeling

Circulation: Heart Failure

Volumn 2, Issue 6, 2009, Pages 624-632

  Dahl, Christen Peder ^a   Husberg, Cathrine ^a,c   Gullestad, Lars ^a   Wæhre, Anne ^a,c   Damås, Jan Kristian ^a   Vinge, Leif Erik ^b   Finsen, Alexandra V ^a,c   Ueland, Thor ^a   Florholmen, Geir ^a,c   Aakhus, Svend ^a   Halvorsen, Bente ^a   Aukrust, Pål ^a   Øie, Erik ^a,c   Yndestad, Arne ^a   Christensen, Geir ^a,c  

^a UNIVERSITY OF OSLO   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

CXCL16; Heart failure; Inflammation; Metalloproteinases remodeling

Indexed keywords

CXCL16 CHEMOKINE; MATRIX METALLOPROTEINASE; STRESS ACTIVATED PROTEIN KINASE;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLLAGEN SYNTHESIS; CONTROLLED STUDY; CORONARY ARTERY LIGATION; DISEASE SEVERITY; EXTRACELLULAR MATRIX; FEMALE; FIBROBLAST; HEART FAILURE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; VASCULITIS; WESTERN BLOTTING;

EID: 77952738714     PISSN: 19413289     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.108.821074     Document Type: Article

References (35)

1. Jessup M, Brozena S. Heart failure. N Engl J Med. 2003;348:2007-2018.
2. Aukrust P, Gullestad L, Ueland T, Damås JK, Yndestad A. Inflammatory and anti-inflammatory cytokines in chronic heart failure: potential therapeutic implications. Ann Med. 2005;37:74-85.
3. Mann DL. Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ Res. 2002;91:988-998.
4. Ludwig A, Weber C. Transmembrane chemokines: versatile 'special agents' in vascular inflammation. Thromb Haemost. 2007;97:694-703.
5. Wilbanks A, Zondlo SC, Murphy K, Mak S, Soler D, Langdon P, Andrew DP, Wu L, Briskin M. Expression cloning of the STRL33/BONZO/TYMSTR ligand reveals elements of CC, CXC, and CX3C chemokines. J Immunol. 2001;166:5145-5154.
6. Smith C, Halvorsen B, Otterdal K, Wæhre T, Yndestad A, Fevang B, Sandberg WJ, Breland UM, Frøland SS, Øie E, Gullestad L, Damås JK, Aukrust P. High levels and inflammatory effects of soluble CXC ligand 16 (CXCL16) in coronary artery disease: down-regulatory effects of statins. Cardiovasc Res. 2008;79:195-203.
7. Chandrasekar B, Bysani S, Mummidi S. CXCL16 signals via Gi, phosphatidylinositol 3-kinase, Akt, I kappa B kinase, and nuclear factor-kappa B and induces cell-cell adhesion and aortic smooth muscle cell proliferation. J Biol Chem. 2004;279:3188-3196.
8. Scholz H, Sandberg W, Damås JK, Smith C, Andreassen AK, Gullestad L, Frøland SS, Yndestad A, Aukrust P, Halvorsen B. Enhanced plasma levels of LIGHT in unstable angina: possible pathogenic role in foam cell formation and thrombosis. Circulation. 2005;112:2121-2129.
9. Iversen PO, Woldbaek PR, Christensen G. Reduced immune responses to an aseptic inflammation in mice with congestive heart failure. Eur J Haematol. 2005;75:156-163.
10. Finsen AV, Christensen G, Sjaastad I. Echocardiographic parameters discriminating myocardial infarction with pulmonary congestion from myocardial infarction without congestion in the mouse. J Appl Physiol. 2005;98:680-689.
11. Dahl CP, Gullestad L, Fevang B, Holm AM, Landrø L, Vinge LE, Fiane AE, Sandberg WJ, Otterdal K, Frøland SS, Damås JK, Halvorsen B, Aukrust P, Øie E, Yndestad A. Increased expression of LIGHT/TNFSF14 and its receptors in experimental and clinical heart failure. Eur J Heart Fail. 2008;10:352-359.
12. Florholmen G, Andersson KB, Yndestad A, Austbø B, Henriksen UL, Christensen G. Leukemia inhibitory factor alters expression of genes involved in rat cardiomyocyte energy metabolism. Acta Physiol Scand. 2004;180:133-142.
13. Halvorsen B, Ranheim T, Nenseter MS, Huggett AC, Drevon CA. Effect of a coffee lipid (cafestol) on cholesterol metabolism in human skin fibroblasts. J Lipid Res. 1998;39:901-912.
14. Florholmen G, Halvorsen B, Beraki K, Lyberg T, Sagen EL, Aukrust P, Christensen G, Yndestad A. Activin A inhibits organization of sarcomeric proteins in cardiomyocytes induced by leukemia inhibitory factor. J Mol Cell Cardiol. 2006;41:689-697.
15. Staff AC, Ranheim T, Henriksen T, Halvorsen B. 8-Iso-prostaglandin f (2alpha) reduces trophoblast invasion and matrix metalloproteinase activity. Hypertension. 2000;35:1307-1313.
16. Yndestad A, Holm AM, Müller F, Simonsen S, Frøland SS, Gullestad L, Aukrust P. Enhanced expression of inflammatory cytokines and activation markers in T-cells from patients with chronic heart failure. Cardiovasc Res. 2003;60:141-146.
17. Øie E, Vinge LE, Tønnessen T, Grøgaard HK, Kjekshus H, Christensen G, Smiseth OA, Attramadal H. Transient, isopeptide-specific induction of myocardial endothelin-1 mRNA in congestive heart failure in rats. Am J Physiol Heart Circ Physiol. 1997;273:H1727-H1736.
18. Halvorsen B, Staff AC, Ligaarden S, Prydz K, Kolset SO. Lithocholic acid and sulphated lithocholic acid differ in the ability to promote matrix metalloproteinase secretion in the human colon cancer cell line CaCo-2. Biochem J. 2000;349:189-193.
19. Kageyama Y, Torikai E, Nagano A. Anti-tumor necrosis factor-alpha antibody treatment reduces serum CXCL16 levels in patients with rheumatoid arthritis. Rheumatol Int. 2008;28:245-251.
20. Nanki T, Shimaoka T, Hayashida K, Taniguchi K, Yonehara S, Miyasaka N. Pathogenic role of the CXCL16-CXCR6 pathway in rheumatoid arthritis. Arthritis Rheum. 2005;52:3004-3014.
21. le Blanc LMP, van Lieshout AWT, Adema GJ, van Riel PLCM, Verbeek MM, Radstake TRDJ. CXCL16 is elevated in the cerebrospinal fluid versus serum and in inflammatory conditions with suspected and proved central nervous system involvement. Neurosci Lett. 2006;397:145-148.
22. Sheikine Y, Bang CS, Nilsson L, Samnegård A, Hamsten A, Jonasson L, Eriksson P, Sirsjö A. Decreased plasma CXCL16/SR-PSOX concentration is associated with coronary artery disease. Atherosclerosis. 2006; 188:462-466.
23. Lehrke M, Millington SC, Lefterova M, Cumaranatunge RC, Szapary P, Wilensky R, Rader DJ, Lazar MA, Reilly MP. CXCL16 is a marker of inflammation, atherosclerosis, and acute coronary syndromes in humans. J Am Coll Cardiol. 2007;49:442-449.
24. + T Cells in cardiac valves during inflammatory valvular heart disease. Arterioscler Thromb Vasc Biol. 2004;24:282-287.
25. Abel S, Hundhausen C, Mentlein R, Schulte A, Berkhout TA, Broadway N, Hartmann D, Sedlacek R, Dietrich S, Muetze B, Schuster B, Kallen KJ, Saftig P, Rose-John S, Ludwig A. The transmembrane CXC-chemokine ligand 16 is induced by IFN-γ and TNF-α and shed by the activity of the disintegrin-like metalloproteinase ADAM10. J Immunol. 2004;172:6362-6372.
26. Wuttge DM, Zhou X, Sheikine Y, Wågsäter D, Stemme V, Hedin U, Stemme S, Hansson GK, Sirsjö A. CXCL16/SR-PSOX is an interferon-γ- regulated chemokine and scavenger receptor expressed in atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 2004;24:750-755.
27. Aukrust P, Ueland T, Lien E, Bendtzen K, Müller F, Andreassen AK, Nordøy I, Aass H, Espevik T, Simonsen S, Frøland SS, Gullestad L. Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 1999;83:376-382.
28. Boyd JH, Mathur S, Wang Y, Bateman RM, Walley KR. Toll-like receptor stimulation in cardiomyoctes decreases contractility and initiates an NF-kappaB dependent inflammatory response. Cardiovasc Res. 2006; 72:384-393.
29. Frantz S, Kobzik L, Kim YD, Fukazawa R, Medzhitov R, Lee RT, Kelly RA. Toll4 (TLR4) expression in cardiac myocytes in normal and failing myocardium. J Clin Invest. 1999;104:271-280.
30. Deschamps AM, Spinale FG. Pathways of matrix metalloproteinase induction in heart failure: bioactive molecules and transcriptional regulation. Cardiovasc Res. 2006;69:666-676.
31. Spinale FG. Matrix metalloproteinases: regulation and dysregulation in the failing heart. Circ Res. 2002;90:520-530.
32. Hu W, Zhen X, Xiong B, Wang B, Zhang W, Zhou W. CXCR6 is expressed in human prostate cancer in vivo and is involved in the in vitro invasion of PC3 and LNCap cells. Cancer Sci. 2008;99:1362-1369.
33. Ruth JH, Haas CS, Park CC, Amin MA, Martinez RJ, Haines GK III, Shahrara S, Campbell PL, Koch AE. CXCL16-mediated cell recruitment to rheumatoid arthritis synovial tissue and murine lymph nodes is dependent upon the MAPK pathway. Arthritis Rheum. 2006;54:765-778.
34. Choukroun G, Hajjar R, Fry S, del Monte F, Haq S, Guerrero JL, Picard M, Rosenzweig A, Force T. Regulation of cardiac hypertrophy in vivo by the stress-activated protein kinases/c-Jun. NH (2)-terminal kinases. J Clin Invest. 1999;104:391-398.
35. De Windt LJ, Lim HW, Bueno OF, Liang Q, Delling U, Braz JC, Glascock BJ, Kimball TF, del Monte F, Hajjar RJ, Molkentin JD. Targeted inhibition of calcineurin attenuates cardiac hypertrophy in vivo. Proc Natl Acad Sci USA. 2001;98:3322-3327.